NEW YORK (GenomeWeb News) – KineMed today announced an agreement with MedImmune to study the effects of a monoclonal antibody on the dynamics of the cellular prion protein.

MedImmune, the biologics research development arm of AstraZeneca, will use KineMed's technology to track the prion protein to gain a better understanding of how an antibody directed at the cellular prion protein may affect turnover and expression of the protein at the cell surface.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.

Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."

Ivan Oransky discusses the need for reproducibility research at The Conversation.

The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.